Table V.

Univariate Cox regression analysis of the overall survival in patients who received adjuvant chemotherapy (gemcitabine or S-1).

Factor	Cut-off point	Gemcitabine			S-1
		No. of patients	Median time (months)	P-value log-rank	No. of patients	Median time (months)	P-value log-rank
ENT1	<4.64	24	25.1	0.044a	4	25.2	0.944
	≥4.64	17	16.7		10	35.1
RRM1	−	27	24.1	0.454	8	27.2	0.126
	+	15	14.0		7	23.3
RRM2	<1.34	22	24.1	0.917	5	35.1	0.172
	≥1.34	17	18.8		9	23.3
TS	<1.34	19	30.60	0.397	7	23.3	0.807
	≥1.34	20	23.30		6	25.4
DPD	<0.53	17	25.1	0.193	11	27.2	0.908
	≥0.53	25	18.8		3	23.3
DHFR	<1.14	13	Not reached	0.329	5	27.2	0.141
	≥1.14	15	18.8		3	21.8
FPGS	<1.21	18	16.8	0.165	8	23.3	0.358
	≥1.21	21	25.1		5	25.4
GGH	−	24	25.1	0.592	11	27.2	0.001a
	+	11	16.9		4	14.4
EGFR	<1.52	19	23.3	0.716	6	23.6	0.763
	≥1.52	20	24.1		5	35.1
VEGF	<6.35	19	Not reached	0.150	9	27.2	0.737
	≥6.35	22	18.8		6	22.6